Merck has announced a major expansion of its filtration and purification technology manufacturing facility in Bengaluru. The upgrade will significantly increase production capacity and strengthen Merck’s global supply chain for critical filtration products used in biopharmaceutical manufacturing.
Glimpse:
The expanded Bengaluru facility will produce a wide range of advanced filtration and purification technologies that are essential for the production of vaccines, monoclonal antibodies, and other biologics. This investment is expected to improve supply reliability, reduce lead times, and better support the growing global demand for bioprocessing solutions.
Merck, a leading science and technology company, is boosting its presence in India by significantly expanding its filtration manufacturing facility in Bengaluru. The move is aimed at enhancing its global supply chain capabilities for high performance filtration and purification products used in the production of life saving biologics and vaccines.
The upgraded facility will house advanced production lines and increase overall manufacturing capacity. These filtration technologies play a critical role in biopharmaceutical manufacturing by ensuring the purity, safety, and quality of medicines. With this expansion, Merck aims to meet rising global demand more efficiently while reducing dependency on single source locations.
This development reinforces Merck’s long term commitment to India as a strategic manufacturing and innovation hub. The Bengaluru site already serves as an important centre for the company’s Life Science business in the region.
The expansion is expected to create additional skilled jobs and further contribute to the growth of India’s biopharmaceutical ecosystem.
“This expansion in Bengaluru underscores our commitment to strengthening the global supply chain for critical bioprocessing technologies and supporting our customers worldwide with reliable, high quality solutions.”
By
HB Team
Related News
